![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ZIOPHARM PRESENTS DATA ON ZIO-101 IN SOLID TUMORS
ZIOPHARM PRESENTS DATA ON ZIO-101 IN SOLID TUMORS
October 4, 2006
Ziopharm Oncology has presented updated clinical data on ZIO-101 at the European Society of Medical Oncology meeting in Istanbul. The safety and dose-ranging study provides substantial evidence of clinical activity in a variety of solid tumors. The company believes that these results warrant an expanded Phase II program in solid tumors in addition to the recently announced Phase II trial program in hematological cancers.
The maximum-tolerated dose (MTD) of ZIO-101, an organic arsenic, was 420 mg/me2 given daily for five consecutive days every four weeks. There were few adverse effects at or below the MTD. The MTD dose of ZIO-101 is more than 50 times the FDA-approved daily dose of arsenic trioxide (Trisenox).
Results from the ongoing Phase I solid tumor trial with ZIO-101 are maturing. Of the 29 subjects receiving ZIO-101, eight have benefited. Seven have stable disease including three with colorectal cancer, two with renal cell cancer one with head and neck cancer and one with a spinal cord tumor. An eighth with pancreatic cancer had a substantial decrease of a liver metastasis.
ZIO-101 is a small molecule that is also in Phase I/II studies in patients with advanced myeloma. In addition to Phase II studies utilizing the established MTD, the company plans to explore alternative dosing schedules in the future.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct